Renaissance Technologies LLC Sells 68,200 Shares of Personalis, Inc. (NASDAQ:PSNL)

Renaissance Technologies LLC lessened its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 6.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,029,311 shares of the company’s stock after selling 68,200 shares during the quarter. Renaissance Technologies LLC owned about 1.98% of Personalis worth $1,204,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. ARK Investment Management LLC lifted its position in Personalis by 4.9% in the second quarter. ARK Investment Management LLC now owns 6,361,886 shares of the company’s stock valued at $7,443,000 after purchasing an additional 296,413 shares during the last quarter. Acadian Asset Management LLC grew its stake in Personalis by 6.7% in the second quarter. Acadian Asset Management LLC now owns 1,057,956 shares of the company’s stock worth $1,237,000 after purchasing an additional 66,128 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in Personalis by 144.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company’s stock worth $1,224,000 after purchasing an additional 485,822 shares during the period. State of Michigan Retirement System grew its stake in Personalis by 11.3% in the first quarter. State of Michigan Retirement System now owns 493,798 shares of the company’s stock worth $736,000 after purchasing an additional 50,000 shares during the period. Finally, GSA Capital Partners LLP grew its stake in shares of Personalis by 6.2% in the first quarter. GSA Capital Partners LLP now owns 420,141 shares of the company’s stock worth $626,000 after acquiring an additional 24,498 shares during the last quarter. Institutional investors own 61.91% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on PSNL. HC Wainwright increased their target price on Personalis from $7.50 to $9.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Needham & Company LLC increased their target price on Personalis from $5.50 to $7.25 and gave the stock a “buy” rating in a research note on Friday, August 16th. Finally, BTIG Research increased their target price on Personalis from $5.50 to $7.00 and gave the stock a “buy” rating in a research note on Friday, August 16th.

Personalis Stock Performance

PSNL stock opened at $5.19 on Friday. Personalis, Inc. has a fifty-two week low of $0.89 and a fifty-two week high of $7.20. The business’s 50-day moving average is $4.97 and its two-hundred day moving average is $2.72. The company has a market cap of $269.56 million, a price-to-earnings ratio of -2.73 and a beta of 1.92.

Personalis (NASDAQ:PSNL) last posted its earnings results on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. The company had revenue of $22.58 million for the quarter, compared to the consensus estimate of $19.81 million. During the same quarter in the prior year, the company earned ($0.50) earnings per share. Equities analysts predict that Personalis, Inc. will post -1.15 earnings per share for the current year.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.